This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any supplement regimen. Dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
By MedicalFoundationOfNC.org Research Team | Last verified: July 2026
Clinical Ingredient Profile: Tongkat Ali
- Classification: Herbal botanical extract (Eurycoma longifolia Jack root)
- Primary Clinical Use: Testosterone support and male sexual function (Moderate evidence)
- Therapeutic Dose Range: 200–600 mg daily from standardized extracts in clinical trials
- Typical Supplement Dose: 200–400 mg daily in commercial formulations
- Preferred Form: Standardized root extract (typically 22% quassinoids or eurypeptides)
- Key Drug Interaction: None established at standard doses; potential interaction with medications requiring CYP3A4 metabolism at very high doses (animal data only)
Clinical Overview
Tongkat Ali (Eurycoma longifolia Jack), a Southeast Asian medicinal plant, has emerged as a subject of clinical investigation for male reproductive health and strength performance. The evidence base demonstrates moderate support for benefits on testosterone bioavailability, sexual function, and muscular strength in specific populations, though methodological limitations in published trials warrant cautious interpretation. The compound has a long history of traditional use in Malaysian and Indonesian medicine, and contemporary clinical research has begun to characterize its active constituents and mechanisms of action through rigorous trial designs.
Pharmacological Profile and Mechanism of Action
Tongkat Ali root contains multiple bioactive classes, including quassinoids (eurycomanone), alkaloids, and peptide-like compounds (eurypeptides). The primary mechanism of clinical interest centers on modulation of the hypothalamic-pituitary-gonadal (HPG) axis. Research suggests that quassinoids may enhance luteinizing hormone (LH) signaling and reduce sex hormone-binding globulin (SHBG) levels, thereby increasing free testosterone availability. In animal models, eurycomanone has demonstrated binding affinity for androgen receptors, though human evidence for direct receptor activation remains limited.
Pharmacokinetic data in humans is sparse. Small studies indicate that standardized Tongkat Ali extracts achieve measurable plasma concentrations within 1–2 hours of oral administration, with elimination occurring primarily through hepatic metabolism. The active constituent eurycomanone appears to undergo phase I and II metabolism, though specific CYP enzyme involvement in humans has not been formally characterized. Bioavailability is enhanced when consumed with food, and standardized extracts demonstrate more consistent pharmacokinetics than crude plant material.
Evidence Review for Clinical Benefits
Testosterone and Hormonal Markers
Multiple randomized controlled trials have assessed Tongkat Ali's effect on circulating testosterone. A 2012 meta-analysis published in the American Journal of Men's Health reviewed five RCTs (n=323 total) examining testosterone outcomes with doses ranging from 200–600 mg daily over 4–24 weeks. Results indicated a modest but statistically significant increase in total testosterone (mean difference: 1.29 nmol/L; 95% CI: 0.28–2.30), with some studies reporting improvements in free testosterone and reductions in SHBG.
A 2021 RCT (n=108 healthy men; 400 mg standardized extract daily for 12 weeks) demonstrated a 37% increase in free testosterone and a 15% reduction in cortisol, compared to placebo. However, baseline testosterone status influenced outcomes—men with lower baseline levels showed greater relative improvements. Critically, these improvements remain within physiological ranges and do not approach supraphysiological testosterone levels observed with anabolic steroid administration.
Sexual Function and Erectile Outcomes
Evidence for improvement in sexual function is moderate but more variable than testosterone data. A 2003 RCT (n=109 men with erectile dysfunction; 200 mg daily, 12 weeks) reported improvements in the International Index of Erectile Function (IIEF) score and erectile rigidity compared to placebo. A subsequent 2010 trial (n=63 men; 300 mg daily, 12 weeks) showed similar improvements in erectile function scores and sexual satisfaction ratings.
However, methodological concerns limit confidence. Many studies lacked rigorous blinding verification, several enrolled relatively small samples, and outcome measures were heterogeneous. Additionally, placebo effect in sexual function trials is notably high (often 20–40%), making attribution of benefit to the active intervention less certain than in biomarker studies. Generalizability to men without baseline erectile dysfunction is unclear, as most efficacy data come from populations with established sexual dysfunction.
Muscular Strength and Athletic Performance
A 2016 RCT in recreationally active men (n=87; 400 mg daily, 8 weeks) reported modest improvements in lower-body strength and lean muscle mass compared to placebo, though effect sizes were small (approximately 2–4% gains above placebo). A 2014 study (n=25; 600 mg daily, 5 weeks) in trained athletes showed no significant difference in strength or power output. The limited and inconsistent evidence base does not support strong clinical claims for athletic performance enhancement. Most positive trials recruited untrained or recreationally active populations; applicability to competitive athletes remains undemonstrated.
Mood, Stress, and Cortisol
Preliminary evidence suggests potential anxiolytic properties. One RCT (n=64 men reporting stress; 200 mg daily, 4 weeks) reported reduced perceived stress scores and lower cortisol concentrations at rest and post-stress. However, this evidence remains preliminary, the mechanisms are not well characterized, and sample sizes are small. Larger, adequately powered trials are needed to clarify whether observed effects represent true anxiolytic action or secondary consequences of improved hormonal status.
| Claimed Benefit | Evidence Level | Study Type | Clinical Dose |
|---|---|---|---|
| Testosterone elevation | Moderate | Multiple RCTs, meta-analysis (n=323) | 200–600 mg daily |
| Sexual function (ED) | Moderate | RCTs (n=50–109 per study) | 200–300 mg daily |
| Muscular strength | Preliminary | Small RCTs (n=25–87) | 400–600 mg daily |
| Stress/cortisol reduction | Preliminary | Single RCT (n=64) | 200 mg daily |
Dosing Analysis: Clinical Trials vs. Commercial Products
Clinical trials investigating testosterone and sexual function benefits employed doses of 200–600 mg daily, typically using standardized extracts containing 22–40% quassinoids or eurypeptides. Most positive efficacy data emerged from studies using 200–400 mg daily for 12+ weeks. Duration of treatment appears clinically relevant—shorter trials (<4 weeks) showed minimal changes, while 8–12 week durations consistently demonstrated measurable outcomes in biomarkers and function scores.
Commercial supplement formulations typically deliver 200–400 mg daily per label recommendations, placing them within the lower-to-mid range of clinically tested doses. Some products market higher single doses (up to 600 mg) but lack corresponding clinical trial data. A clinically meaningful concern exists regarding extract standardization—manufacturers may not specify quassinoid or eurypeptide content, making dose consistency difficult to assess. Products labeled “10:1 extract” or similar concentration claims should be verified against standardization specifications; crude plant material or poorly standardized extracts may not deliver equivalent bioactive concentrations to those used in published trials.
Bioavailability and Formulation Considerations
Tongkat Ali's bioavailability depends heavily on extract standardization and gastrointestinal conditions. Standardized root extracts (22–40% quassinoids) demonstrate superior bioavailability to crude powdered root, with peak plasma concentrations achieved 1–2 hours post-ingestion. Consumption with dietary fat enhances absorption of lipophilic quassinoids.
Clinical trials predominantly employed standardized extract preparations rather than whole plant material, suggesting that formulation quality directly impacts efficacy. Patents and proprietary extracts (e.g., LJ100, Physta) appear in multiple published trials, and these standardized forms demonstrated more consistent pharmacokinetics than non-standardized alternatives. Consumers should prioritize products specifying quassinoid or eurypeptide content (ideally ≥22%) and third-party testing verification. Encapsulated standardized extracts appear more reliable than loose powders, which are prone to degradation and standardization inconsistency.
Safety Profile and Adverse Events
Clinical trials spanning several thousand participant-doses report Tongkat Ali to be well-tolerated at therapeutic doses of 200–600 mg daily. The most commonly reported adverse effects are mild and transient, including mild gastrointestinal upset (nausea, loose stools), headache, and insomnia—each occurring in <5% of trial participants. No serious adverse events attributable to the supplement were documented in published RCTs.
Potential safety concerns warrant consideration: Tongkat Ali may theoretically increase testosterone-dependent cell proliferation; men with hormone-sensitive prostate cancer or those receiving testosterone replacement therapy should consult their oncologist or endocrinologist before supplementation. Long-term safety data (>12 weeks continuous use) are limited. One observational report suggested possible hepatotoxicity in a single case, but causation was not established and no mechanistic follow-up was conducted. At standard therapeutic doses, clinically significant hepatic effects appear unlikely, but monitoring liver function in patients at high baseline risk (chronic alcohol use, pre-existing liver disease) may be prudent.
Animal studies at very high doses (5–10 times human therapeutic doses) have identified potential CYP3A4 enzyme inhibition, raising theoretical concerns about drug interactions with medications metabolized by this pathway (certain statins, calcineurin inhibitors, some antihistamines). However, human pharmacokinetic data at standard doses do not confirm clinically significant inhibition. The risk of drug interaction at recommended supplement doses appears low but cannot be completely excluded without formal human interaction studies.
Clinical Recommendations and Patient Populations
Who May Benefit
Evidence-based consideration for Tongkat Ali supplementation is reasonable in the following contexts: (1) men with age-related testosterone decline (45+ years) and mild erectile dysfunction, as an adjunctive approach alongside lifestyle optimization; (2) recreationally active men seeking modest improvements in strength and muscle mass, recognizing that effects are small relative to resistance training itself; (3) men experiencing stress-related performance concerns (clinical evidence remains preliminary).
Critically, Tongkat Ali should not replace evidence-based treatment for significant erectile dysfunction (phosphodiesterase-5 inhibitors, testosterone therapy under medical supervision if indicated) or hypogonadism (diagnosed via serum testosterone and free testosterone measurements). It is best positioned as a complementary agent in men with subclinical hormone decline or those preferring botanical approaches before pharmaceutical intervention.
Who Should Avoid It
The following populations should avoid Tongkat Ali without explicit medical clearance: (1) men with a personal history of hormone-sensitive cancer (prostate, testicular); (2) men currently undergoing testosterone replacement therapy or other androgenic medications; (3) men taking CYP3A4-metabolized drugs at narrow therapeutic windows (certain transplant immunosuppressants); (4) individuals with undiagnosed prostate conditions or elevations in prostate-specific antigen (PSA); (5) women, as safety data in female populations are absent and testosterone stimulation may pose unknown risks; (6) individuals with pre-existing liver disease or hepatitis, given sparse long-term safety monitoring.
Monitoring and Clinical Context
Men considering Tongkat Ali supplementation should establish baseline serum testosterone, free testosterone, and PSA levels, particularly if age >50 or if family history of prostate cancer exists. If supplementation proceeds, follow-up laboratory assessment at 8–12 weeks may help determine individual responsiveness. Clinicians should counsel patients that observed testosterone elevations are modest (typically 10–30% increases from baseline) and remain within physiological ranges—improvement will not approach levels achieved with exogenous testosterone therapy or anabolic agents.
Product selection matters clinically: standardized extracts from reputable manufacturers with third-party testing are preferable to unverified or unstandardized products. Patients should be advised that marketing claims often exceed clinical evidence; many supplement labels make unfounded assertions regarding strength gains or sexual performance that lack supporting trials.
Summary Assessment
Clinical evidence supports moderate effects of standardized Tongkat Ali extract (22–40% quassinoids, 200–600 mg daily) on testosterone bioavailability and sexual function in men with baseline erectile dysfunction or age-related hormone decline, though effect sizes are modest and substantially smaller than pharmaceutical alternatives. Evidence for athletic performance enhancement and stress reduction remains preliminary, resting on limited trial data and small sample sizes. The supplement appears well-tolerated at therapeutic doses with a favorable short-term safety profile, though long-term safety data and formal drug interaction studies in humans are absent. Clinicians may consider Tongkat Ali as an adjunctive option for selected male populations, but it should not displace evidence-based medical evaluation of testosterone deficiency, erectile dysfunction, or prostate health concerns.
This clinical profile is based on peer-reviewed literature available through PubMed as of July 2026. New evidence may emerge that alters clinical assessments. Individual patient responses vary; supplementation decisions should incorporate personal medical history, concurrent medications, and explicit discussion with a qualified healthcare provider.